A Modular Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of AZD2962, an IRAK4 inhibitor, as Monotherapy and in Combination with other Agents, in Participants with Hematologic Neoplasms

Dysplastic chronic myelomonocytic leukaemia, Myelodysplastic syndromes

Incidence of DLTs during the DLT observation period., Incidence, severity, and relationship to IMP, of AEs and SAEs., Changes from baseline in laboratory evaluations, vital signs, physical examinations, and ECG results., Duration of exposure and relative dose intensity.

Objective Response, as assessed by the response criteria corresponding to the different haematologic neoplasms., Duration of Response, Time to Response, Overall Survival, and Time to progression to AML., Plasma concentrations of AZD2962., Plasma PK parameters of AZD2962 (including but not limited to AUC, Cmax, and tmax, as data allow).

No related papers found yet.

Spain